Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2021 · 10-Q
Revenue$130.93M$130.93M+37.9% vs Q1 2020 Net Income$5.69M$5.69M−73.5% vs Q1 2020 EPS Diluted$0.11$0.11−72.5% vs Q1 2020 Operating Income$13,214,000−54.5% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived$34,692,000+443.8% Margins · derivedOperating margin10.1%−20.5 pt vs Q1 2020
Net margin4.3%−18.3 pt vs Q1 2020
ended Mar 31, 2021 · filed May 7, 2021 · 37 d after period end